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Abstract
Background. Optimal management for recurrent IDH-mutant glioma after radiation therapy (RT) is not well-defined.
This study assesses practice patterns for managing recurrent IDH-mutant astrocytoma (Astro) and 1p/19q codeleted
oligodendroglioma (Oligo) after RT and surveys their clinical outcomes after different salvage approaches.
Methods. Ninety-four recurrent Astro or Oligo patients after RT who received salvage systemic therapy (SST) between 2001 and 2019 at a tertiary cancer center were retrospectively analyzed. SST was defined as either alkylating
chemotherapy (AC) or nonalkylating therapy (non-AC). Overall survival (OS) and progression-free survival (PFS)
were calculated using the Kaplan-Meier method from the start of SST. Multivariable analysis (MVA) was conducted
using Cox regression analysis.
Results. Recurrent Oligo (n = 35) had significantly higher PFS (median: 3.1 vs 0.8 years, respectively, P = .002) and
OS (median: 6.3 vs 1.5 years, respectively, P < .001) than Astro (n = 59). Overall, 90% of recurrences were local.
Eight-three percent received AC as the first-line SST; 50% received salvage surgery before SST; approximately 50%
with local failure >2 years after prior RT received reirradiation. On MVA, non-AC was associated with worse OS for
both Oligo and Astro; salvage surgery was associated with improved PFS and OS for Astro; early reirradiation was
associated with improved PFS for Astro.
Conclusions. Recurrent radiation-relapsed IDH-mutant gliomas represent a heterogeneous group with variable
treatment approaches. Surgery, AC, and reirradiation remain the mainstay of salvage options for retreatment.

Key Points
• Recurrent IDH-mutant oligodendroglioma has significantly better clinical outcomes than
recurrent IDH-mutant astrocytoma.
• Alkylating chemotherapy should be considered first-line salvage systemic therapy for
recurrent IDH-mutant glioma.
• Reirradiation with concurrent temozolomide is feasible and safe in recurrent IDH-mutant
glioma.
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/
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Importance of the Study

Diffuse gliomas are a heterogeneous set of central nervous
system tumors, and the 2016 World Health Organization
classification has incorporated molecular markers in their
diagnoses, including the isocitrate dehydrogenase (IDH)
mutation as a key marker.1 IDH-mutant gliomas have a significantly better prognosis than IDH-wildtype gliomas.2
IDH-mutant astrocytoma is typically characterized by ATRX
loss or absence of 1p/19q codeletion, and IDH-mutant oligodendroglioma is typically characterized by 1p/19q codeletion
or mutation of the TERT promoter.3–5 Currently, the standard
of care for IDH-mutant astrocytoma and oligodendroglioma
consists of maximum safe resection followed by radiation therapy (RT) with chemotherapy (either temozolomide
[TMZ] or procarbazine, lomustine, and vincristine [PCV]).6–8
However, there is limited available data to guide optimal
salvage therapy at recurrence after chemoradiotherapy.9
As there is increasing interest to develop novel therapies
for these patients at recurrence, a thorough understanding
of the pattern of care for recurrent IDH-mutant gliomas and
their natural history after existing salvage therapies will
be crucial to guide clinical practice and future clinical trial
development.
To address this unmet need, we retrospectively analyzed
our tertiary care center’s experience of treating recurrent
IDH-mutant astrocytomas (Astro) and 1p/19q codeleted
oligodendrogliomas (Oligo) to establish an overview of the
pattern of care, evaluate for prognostic factors to guide risk
stratification, and survey the impact of different salvage
therapies.

Methods
Patient Cohort
We conducted a single-institution retrospective review of
adult patients (≥18 years old) with either Astro or Oligo who
developed recurrence after initial RT and who had received
salvage systemic therapy (SST). Recurrence was considered a local failure (LF) if, within the initial RT field, focal
distant failure (fDF) if a single site of recurrence outside of

therapy whenever possible. Consistent with
previously reported outcomes, our results indicate that salvage surgery may prolong survival
for recurrent glioma, a benefit possibly further
enhanced in Astro. Reirradiation was associated
with nonsignificant trends towards improved
survival and could safely be combined with AC,
but its observed benefit may be confounded by
selection bias. Our data support multimodality
management of recurrent IDH-mutant glioma
and highlights the need to identify other active
systemic agents for AC-refractory disease.

the RT field, or disseminated distant failure if more than
one site of distant recurrence or leptomeningeal disease
(dDF). Glioblastoma with 1p/19q codeletion but without
IDH mutation were excluded. Oligo was defined as histological oligodendroglioma or mixed oligoastrocytoma
with 1p/19q codeletion. Astro was defined as glioma
with IDH mutation but was either negative for 1p/19q
codeletion or positive for ATRX loss. 1p/19q codeletion
was assessed by fluorescence in situ hybridization (FISH)
and was routinely performed at our institution for histological oligodendroglioma and mixed oligoastrocytoma
since 1999. IDH mutation and ATRX loss were evaluated
by either immunohistochemistry (IHC) or next-generation
sequencing (NGS) as previously described.10 Although
some of our patients were before the routine testing of IDH
at our institution (which started in 2012), their IDH status
was determined a posteriori based on the later analysis of
tumor samples. Oligo without confirmed IDH mutation was
included as long as it was not shown to be IDH-wildtype
on NGS. Tumor grade at recurrence was defined by pathological evaluation if surgery or biopsy was performed; if
no specimen was obtained, the original pathological diagnosis was used. This study was conducted with the approval of the institutional review board.

Salvage Systemic Therapy
Only first-line SST was analyzed for this study and was
categorized as either alkylating chemotherapy (AC) or
nonalkylating therapy (non-AC). AC included TMZ, PCV,
or lomustine. Non-AC included bevacizumab, immunotherapy (either vaccine or anti-PD-1 antibody), biological
agents, or tumor-treating field (TTF).

Salvage Surgery
Surgeries before SST were analyzed and were categorized
as biopsy, laser interstitial thermal therapy (LITT), subtotal
resection (STR), or gross-total resection (GTR) based on
operative and imaging reports by the treating physicians.
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Management of IDH-mutant glioma in the setting of recurrence is not well-defined. This
study details our institution’s experience with
treating patients with these tumors who developed the recurrent disease after initial radiation therapy. We report treatment patterns
and clinical outcomes of a retrospective cohort with IDH-mutant astrocytoma (Astro) and
1p/1q codeleted oligodendroglioma (Oligo).
Alkylating chemotherapy (AC) demonstrated
improved overall survival (OS) compared with
non-AC, suggesting that these agents should
be employed as first-line salvage systemic
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for Social Sciences, version 23.0 (IBM SPSS Statistics,
Chicago, IL, USA).

Early reRT was defined if delivered either concurrently
or sequentially with the first-line SST, and delayed reRT
was defined if delivered after progression on the initial
SST. ReRT techniques included photon-based intensitymodulated RT (IMRT) using the Varian Medical Systems
linear accelerators (Palo Alto, CA), proton beam therapy
(PBT) using the Mevion Medical Systems proton accelerator (Littleton, MA), or stereotactic radiosurgery (SRS)
using Gamma Knife (Elekta, Atlanta, GA). Gross tumor
volume (GTV) included the surgical cavity of the salvage
surgery if performed as well as the progressive T1 and
T2 abnormality. For external beam RT (EBRT) using either IMRT or PBT, a clinical target volume (CTV) margin
of approximately 0–5 mm from GTV was applied by the
treating physician based on the clinical assessment,
and a planning target volume (PTV) margin of approximately 3 mm was applied to account for setup uncertainty. SRS typically treated only GTV without additional
CTV and PTV margin expansion. RT fractionation and
critical structure constraints were individualized by the
treating physician based on the tumor location and the
previous radiation exposure. A composite plan was
made with the previous EBRT whenever possible. PBT
dose was prescribed as gray relative biological equivalents (GyRBE) using a relative biological effectiveness
(RBE) value of 1.1. To allow the cumulative dose to the
normal brain tissue from different RT courses, biologically equivalent doses in 2 Gy fractions (EQD2) were
estimated for each course using the linear-quadratic
model: EQD2 = Nd × (d + α/β)/(2 + α/β), where N is the
number of fractions, d is the dose per fraction, and α/β of
3 is used for brain tissue.

Statistical Analysis
Baseline patient, tumor, and treatment characteristics were
compared using the Mann-Whitney U test and Fisher’s
Exact test for continuous and categorical variables, respectively. Freedom-from progression (FFP), progression-free
survival (PFS), and overall survival (OS) rates were calculated using the Kaplan-Meier method from the start of SST
and then compared using the log-rank test. Univariable
(UVA) and multivariable analyses (MVA) to identify prognostic factors for PFS and OS were performed using Cox
regression. MVA was performed with all variables with
P < .20 on UVA using the backward-conditional method.
Symptomatic radiation necrosis (sRN) was characterized as previously described and was defined as grade 2
or higher based on the Common Terminology Criteria for
Adverse Events (CTCAE) v4.0.11 Briefly, it was defined as a
radiologic abnormality that resulted in medical or surgical
therapy and excluded tumor progression through surgical evaluation or serial MRI. Time to sRN was measured
from the start of reRT. All tests were two-sided, and statistical analyses were performed with the Statistical Package

Results
Patient and Treatment Characteristics
Between 2001 and 2019, 108 patients with grade 2–4
gliomas with IDH mutation or 1p/19q codeletion developed recurrence after prior RT or chemoradiotherapy and
were captured in our institutional database at Washington
University in St Louis. Six patients had IDH-wildtype GBM
and were excluded. Eight patients were excluded for lack
of follow-up: 4 went to another facility for salvage treatment, 3 went to hospice, and one had no additional follow-up. The remaining 94 patients received SST, including
35 Oligo and 59 Astro. Before the SST, 20 patients had prior
RT alone, 71 had RT and one line of chemotherapy (90%
TMZ and 10% PCV), and 3 had RT and 2 lines of chemotherapy (TMZ and PCV). Among the 35 Oligo patients, 11
had RT alone, 22 had RT and one line of chemotherapy
(82% TMZ), and 2 had RT and 2 lines of chemotherapy.
Among the 59 Astro patients, 9 had RT alone, 49 had RT
and one line of chemotherapy (94% TMZ), and 1 had RT
and 2 lines of chemotherapy. Figure 1 depicts the pattern
of salvage therapy approaches stratified by tumor type, recurrence pattern, and timing since initial RT. Of the 35 Oligo
patients, 17 did not have IDH evaluation. However, based
on our previous study, the FISH assay’s false positive rate
of 1p/19q codeletion to detect a molecular IDH-mutant and
1p/19q codeleted oligodendroglioma is only approximately
2%.12 Table 1 summarizes baseline patient and treatment
characteristics of the study cohort. The median age was
42 years, and 73% were male. The median time to recurrence after initial RT was significantly longer for Oligo than
Astro (7.7 years vs 3.3 years, P = .01). The most common
type of recurrence was LF (90%), and rarely fDF (5%) or dDF
(5%). Among 12 initially grade 2 Oligo patients who had repeat biopsy or surgery at recurrence, 50% had transformed
into grade 3 after a median interval of 10.4 years (range:
6.2–26.0). Among 17 initially grade 2 Astro patients who
had repeat surgery at recurrence, 65% had transformed
into grade 3–4 after a median interval of 6.5 years (range:
2.6–16.7). Among 12 initial grade 3 Astro patients who had
repeat surgery, 50% had transformed into grade 4 after a
median interval of 3.4 years (range: 0.7–15.3). Fifty percent
of the entire cohort had salvage surgeries before SST, and
more than 50% of patients with LF had salvage surgeries
(61% for Oligo and 53% for Astro). Of all the salvage surgeries, 13% were performed with LITT. Overall, 37% received either early or delayed reRT, including 56% of Oligo
and 50% of Astro patients with LF >2 years after initial RT.
Most patients with DF (80%) received reRT, and patients
with LF <2 years after initial RT rarely had reRT (4%). The
most common first-line SST was TMZ (70%), followed by a
lomustine-based regimen (13%) and a bevacizumab-based
regimen (10%). The remaining regimens included anti-PD-1
antibody or T-cell vaccine (3%), TTF (2%), anti-PD1 plus TTF
(1%), and mTOR inhibitor (1%).
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108 recurrent grade 2–4 glioma
with IDH mutation or 1p/19q
codeletion after RT

94 patients treated with
salvage chemotherapy

Oligodendroglioma n = 35

Focal LF n = 33
(61% s/p Surgery/LITT)

>2yr since RT n = 23

IDHmt Astrocytoma n = 59

Focal LF n = 51
(53% s/p Surgery/LITT)

Focal DF n = 2

<2yr since RT n = 10

>2yr since RT n = 34

Focal DF (n = 3)

<2yr since RT n = 17
AC+reRT
n=2

AC+reRT
n=2
AC
n = 18

AC+reRT
n=4
(3 EBRT;
1 SRS)

Non-AC
n=1

AC
n=7

Delayed
reRT
n=9

Non-AC
n=3

AC
n = 17

AC+reRT
n = 13
(11 EBRT;
2 SRS)

Non-AC
n=4

Disseminated (n = 5)

AC
n = 10

Non-AC
n=6

Non-AC
n=1

AC
n=5

Non-AC+reRT
n=1

Delayed
reRT
n=4

Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagram of the salvage treatment approaches for the study patients stratified
by tumor type, recurrence pattern, and timing. IDH = isocitrate dehydrogenase, RT = radiation therapy, IDHwt = IDH-wildtype, GBM = glioblastoma, LF = local failure, DF = distant failure, LITT = laser interstitial thermal therapy, AC = alkylating chemotherapy, Non-AC = nonalkylating therapy,
reRT = reirradiation.
  

Outcomes After Recurrence

Reirradiation With Temozolomide

After a median follow-up of 1.3 years, the median PFS
and OS for the entire cohort after recurrence were 0.9
and 1.5 years, respectively. Oligo patients had significantly higher FFP (median: 3.1 vs 0.8 years, respectively,
P = .006; Figure 2A), PFS (median: 3.1 vs 0.8 years, respectively, P = .002; Figure 2B), and OS (median: 6.3
vs 1.5 years, respectively, P < .001; Figure 2C) as compared to Astro patients. Given the significantly different
natural history of recurrent Oligo vs Astro, MVA to explore prognostic factors was performed separately for
each cohort. For the Oligo cohort, increased age and
non-AC were associated with the significantly worse
OS on MVA (Table 2). For the Astro cohort, lower tumor
grade and salvage surgery were associated with significantly better PFS and OS. Non-AC use was associated
with worse OS. Early reRT was associated with higher
PFS (Table 3). Among a more homogeneous subset of
Astro patients who experienced LF >2 years after initial
RT, 17 patients received AC alone, while 11 patients received AC+EBRT. The baseline characteristics of these
two subsets are shown in Supplementary Table S1. The
most significant difference is that the AC+EBRT cohort had a longer disease-free interval from the initial
RT than the AC alone cohort (median 10.5 vs 3.6 years,
P = .004). AC+EBRT also had nonsignificantly higher proportion of grade 4 disease (46% vs 24%, P = .11) and salvage surgery (73% vs 41%, P = .14). FFP, PFS, and OS
were nonsignificantly higher for AC+EBRT than AC alone
(Figure 2D–F).

Eighteen patients (7 Oligo and 11 Astro) received repeat
EBRT (6 IMRT, 12 PBT) in combination with AC to a previously irradiated region of LR (14 early reRT and 4 delayed
reRT). All received TMZ with reRT: 13 patients with concurrent and adjuvant TMZ, and 5 with only adjuvant TMZ. The
median time from the initial RT to reRT was 11.3 years (range:
2.4–26.2). The median RT dose was 37.8 Gy (range: 35–54
Gy). Most regimens were standard fractionation at 1.8–2
Gy/fr, but two patients were treated with hypofractionated
EBRT (40.05 Gy at 2.67 Gy/fr and 35 Gy at 3.5 Gy/fr). After a
median follow-up of 13.3 months from the start of reRT, the
2-yr FFP was 61%, 2-yr PFS was 71%, and 2-year OS was
75%. There were 3 grade 3 sRN and 1 grade 2 sRN, but none
when cumulative EQD2 was < 100 Gy (Figure 3A, B). The
median time to RN was 9.9 months (range 6.8–11.7). There
was no reported optic neuropathy or brainstem necrosis.
All but one patient had available dosimetric data from the
reRT course for dose-volume histogram analysis, and 14
patients also had composite RT plans. The median PTV was
61 cm3 (range: 12–456 cm3). The median cumulative EQD2 to
the brain was 95 Gy (range: 86–107). The median maximum
dose to the optic apparatus from the second course RT was
7 Gy (range: 0–27), with only 1 patient receiving dose >25
Gy (Figure 3C), and 2 patients received >80 Gy of maximum
cumulative dose to the optic apparatus (Figure 3D). The median maximum dose to the brainstem was 7 Gy (range: 0–37
Gy), with only 1 patient receiving dose > 35 Gy (Figure 3E),
and 2 patients received 90 Gy of maximum cumulative dose
to the brainstem (Figure 3F).
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Baseline Patient and Treatment Characteristics

Baseline Factors

Oligo

Astro

Oligo

35

35

–

Astro

P-value
–

59

–

59

Median Age

42 (23–75)

46 (23–75)

40 (23–70)

.07

Male

69 (73%)

30 (86%)

39 (66%)

.053

Female

25 (27%)

5 (14%)

20 (34%)

White race

89 (95%)

35 (100%)

54 (92%)

Nonwhite race

5 (5%)

Grade at relapsea

<.001

2

22 (23%)

10 (29%)

12 (20%)

3

44 (47%)

25 (71%)

19 (32%)

4

28 (30%)

Time to recurrence from initial RT to SST (years)

.15

5 (9%)

28 (48%)

3.6 (0.2–26.2)

7.7 (0.5–26.2)

3.3 (0.2–16.7)

Chemoradiotherapy

74 (79%)

24 (69%)

50 (85%)

RT alone

20 (21%)

11 (31%)

9 (15%)

LF

84 (89%)

33 (94%)

51 (86%)

fDF

5 (5%)

2 ((6%)

3 (5%)

dDF

5 (5%)

–

5 (9%)

None/biopsy

47 (50%)

15 (43%)

32 (54%)

Surgery/LITT

47 (50%)

20 (57%)

27 (46%)

Prior Treatment

.01
.07

Type of recurrence

.21

Surgery before SST

.39

SST Type

.59

TMZ regimen

66 (70%)

25 (71%)

41 (70%)

Lomustine regimen

12 (13%)

6 (17%)

6 (10%)

Bevacizumab regimen

9 (10%)

2 (6%)

7 (12%)

Other

7 (7%)

2 (6%)

5 (8%)

No

72 (77%)

29 (83%)

43 (73%)

Yes

22 (23%)

6 (17%)

16 (27%)

Early reRT

.32

Oligo = 1p/19q codeleted oligodendroglioma; Astro = IDH-mutant astrocytoma; RT = radiation therapy; SST = salvage systemic therapy; LF = local
failure within prior RT field; fDF = focal distant failure outside of prior RT field; dDF = disseminated distant failure; LITT = laser interstitial thermal
therapy; TMZ = temozolomide; reRT = reirradiation.
aFor tumors that did not have a repeat surgery or biopsy at the time of recurrence, the initial tumor grade was assumed.

  
Discussion
This study reports our institutional experience treating
radiation-relapsed Astro and Oligo. Recurrent Astro exhibited significantly worse clinical outcomes than recurrent Oligo. More than 50% of lower grade Astro or
Oligo transformed to higher grade disease at recurrence.
Approximately half of the cohort received salvage surgery before SST, and approximately half of those with LF
>2 years after initial RT also received reRT. Notably, Astro
appeared to benefit from local therapy, including salvage
surgery and early reRT. The most common type of initial

SST was AC, which was associated with improved OS
than non-AC. Early reRT appeared to be more commonly
offered for recurrent Astro, fDF, or LF >2 years after the initial RT. Due to selection bias, the benefit of reRT could not
be ascertained from this retrospective study. However, selective reRT using EBRT in combination with TMZ appears
feasible with an acceptable risk of sRN.
Our study demonstrates markedly different survival
outcomes between radiation-relapsed Oligo and Astro patients. While many studies have established the superior
disease control and survival of Oligo over Astro in the upfront setting, our report contributes to the emerging literature suggesting that this difference persists at recurrence.3
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B
80
1p/19q codeleted
Oligodendroglioma

60
40
20
0

IDHmutant Astrocytoma

0

No. at risk:
Oligo: 35
Astro: 59

1

2

3

4

5

Time (mos)
22
19

18
11

15
8

14
7

D

E

100
80

Progression-free Survival (%)

P = 0.06
AC + EBRT

60
40
AC

20
0

0

No. at risk:
17
AC:
AC + EBRT: 11

.5

1.0

1.5

2.0

Time (yrs)
11
10

5
7

4
5

3
4

100

P = 0.002

80

1p/19q codeleted
Oligodendroglioma

60
40
20
0

IDHmutant
Astrocytoma
0

No. at risk:
Oligo: 35
Astro: 59

9
6

C

100

Overall Survival (%)

Progression-free Survival (%)

P = 0.006

1

2

3

4

23
20

20
12

17
9

15
7

10
6

AC + EBRT

60
40
AC
20
0

0

No. at risk:
17
AC:
AC + EBRT: 11

.5

1.0

1.5

6
8

4
6

3
5

IDHmutant
Astrocytoma

20

0

1

2

3

4

5

19
8

13
6

Time (yrs)
28
31

23
18

21
11

100

P = 0.07
AC + EBRT

80
60

AC

40
20
0

2.0

Time (yrs)
12
10

40

0

P = 0.06

80

60

No. at risk:
Oligo: 35
Astro: 59

F

100

P < 0.001

1p/19q codeleted
Oligodendroglioma

80

5

Time (yrs)

Overall Survival (%)

100

0

.5

1.0

1.5

2.0

9
6

5
6

Time (yrs)

No. at risk:
17
AC:
AC + EBRT: 11

16
11

10
10

Figure 2. (A–C) Freedom-from progression (FFP), (PFS), and (OS) of recurrent 1p/19q codeleted oligodendroglioma (Oligo) versus IDH-mutant
astrocytoma (Astro). (D-F) FFP, PFS, and OS of the subset of Astro patients with local failure > 2 years after prior RT who received either alkylating
chemotherapy alone (AC) or AC plus repeat external beam radiation therapy (AC+EBRT).
  

  
Table 2.

Univariable and Multivariable Cox Regression Analysis for Factors Associated with Worse PFS and OS for Oligodendroglioma
UVA for PFS

MVA for PFS

UVA for OS

MVA for OS

HR (95% CI)

Pvalue

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

Pvalue

Median age

1.03 (0.99–1.06)

.15

1.03 (0.99–1.06)

.15

1.04 (1.00–1.08

.08

1.06 (1.02–1.11)

.008

Male

1.86 (0.54–6.39)

.33

–

–

5.18 (0.65–41.3)

.12

NS

NS

N/A

–

–

N/A

–

–

Nonwhite race

N/A

N/A

Grade 3 at relapse

0.99 (0.36–2.68)

.98

–

–

1.26 (0.36–4.38)

.72

–

–

Time to recurrence
(months)

1.04 (0.97–1.11)

.30

–

–

1.04 (0.97–1.12)

.30

–

–

Prior
Chemoradiotherapy
(vs RT alone)

0.79 (0.33–1.88)

.59

–

–

0.60 (0.22–1.62)

.31

–

–

fDF (vs LF)

1.17 (0.27–5.07)

.83

–

–

1.79 (0.40–7.98)

.44

–

–

Salvage surgery/LITT

1.43 (0.60–3.38)

.42

–

–

1.03 (0.40–2.69)

.95

–

–

Nonalkylating
therapy

1.88 (0.54–6.50)

.32

–

–

2.55 (0.73–8.95)

.15

8.82 (1.74–44.7)

.009

Early reRT

1.48 (0.58–3.81)

.41

–

–

2.59 (0.95–7.07)

.06

NS

NS

RT = radiation therapy; LF = local failure within prior RT field; fDF = focal distant failure outside of prior RT field; dDF = disseminated distant failure;
LITT = laser interstitial thermal therapy; reRT = reirradiation.

  
Miller et al recently described their institutional outcomes
of recurrent IDH-mutant gliomas and observed higher PFS
for Oligo than Astro (median PFS of 4.2 years vs 2.6 years,
respectively).13 Thus, future clinical trials of recurrent IDHmutant gliomas should consider stratifying for these two
molecular cohorts.
Salvage surgery remains an important consideration for
the management of recurrent IDH-mutant gliomas. Our

results indicate that approximately 50% of lower grade
Astro or Oligo may have progressed to higher grade at recurrence, so repeat sampling through biopsy or resection
should be strongly considered in establishing an accurate
staging. Ramakrishna et al have previously reported their
experience of 52 grade 2 gliomas who had reoperation
after recurrence and demonstrated that the extent of resection (EOR) of the reoperation was prognostic for OS
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Univariable and Multivariable Cox Regression Analysis for Factors Associated with Worse PFS and OS for IDH-Mutant Astrocytoma
UVA for PFS

MVA for PFS

UVA for OS

MVA for OS

P-value

HR (95% CI)

P-value

HR (95% CI)

P value

HR (95% CI)

P-value

Median age

0.97 (0.95–1.00)

.046

NS

NS

0.98 (0.96–1.01

.20

NS

NS

Male

1.59 (0.83–3.06)

.16

NS

NS

2.05 (1.01–4.17)

.047

3.05 (1.35–6.87)

.007

Nonwhite
race

2.56 (0.97–6.77)

.06

NS

NS

2.87 (1.08–7.65)

.04

NS

NS

Grade

.06

.003

.09

.03

Grade 2

Ref

–

Ref

–

Ref

–

Ref

–

Grade 3

1.88 (0.75–4.69)

.18

3.73 (1.37–10.2)

.01

2.02 (0.79–5.18)

.15

3.78 (1.37–10.4)

.01

Grade 4

2.83 (1.19–6.72)

.02

4.80 (1.94–11.9)

.001

2.66 (1.11–6.38)

.03

3.19 (1.15–8.81)

.03

Time to
recurrence
(months)

0.03 (0.00–347.4)

.46

–

–

0.91 (0.83–
0.995)

.04

NS

NS

Prior
Chemoradio
therapy (vs
RT alone)

0.60 (0.25–1.43)

.25

–

–

0.49 (0.17–1.37)

.17

NS

NS

dDF (vs LF/
fDF)

2.45 (0.93–6.43)

.07

NS

NS

2.19 (0.76–6.33)

.15

NS

NS

Salvage surgery/LITT

0.36 (0.19–0.69)

.002

0.31 (0.16–0.60)

.001

0.40 (0.21–0.78)

.007

0.36 (0.18–
0.73)

.005

Nonalkylating
therapy

3.24 (1.58–6.63)

.001

NS

NS

3.33 (1.62–6.84)

.001

2.78 (1.11–6.92)

.03

Early reRT

0.48 (0.23–1.01)

.054

0.43 (0.19–0.95)

.04

0.49 (0.22–1.11)

.09

NS

NS

RT = radiation therapy; LF = local failure within prior RT field; fDF = focal distant failure outside of prior RT field; dDF = disseminated distant failure;
LITT = laser interstitial thermal therapy; reRT = reirradiation.

  
and PFS. Sixty percent of their cohort were radiationrelapsed gliomas, but molecular classification including
IDH and 1p/19q status was not known.14 Our findings are
overall consistent with their observation but also suggest
that recurrent Astro may derive a more significant benefit
from salvage surgery than Oligo, which echoes the observations that the EOR appears to have a more considerable prognostic impact for newly diagnosed Astro than
Oligo.15–17 This discrepancy may be due to the more indolent natural history and enhanced sensitivity of Oligo to
adjuvant therapies compared to Astro.16,17 Whether this
discrepancy should influence the surgical approach of recurrent IDH-mutant gliomas may deserve further investigation. We also observed an emerging trend of LITT as
another surgical approach to treat recurrent IDH-mutant
gliomas. LITT is minimally invasive and may affect the
blood-brain barrier and tumor micro-environment, so its
role in managing recurrent IDH-mutant gliomas also deserves further investigation.18–20
In the current study, AC appears to be the more popular
and more effective SST than non-AC. Previous studies
have demonstrated objective response rates (ORR) of
50–60% for TMZ and PCV.21,22 Taal et al. previously described a cohort of 58 radiation-relapsed low-grade
astrocytomas (86% IDH-mutant) treated with salvage TMZ
and observed an ORR of 54%.21 Van Den Bent et al previously reported a multi-institutional retrospective study
of 52 radiation-relapsed histological oligodendrogliomas
or mixed oligoastrocytomas (IDH and 1p/19q status not

available) treated with salvage PCV and observed an ORR
of 63%.22 Multiple prospective studies have also demonstrated promising PFS outcomes by rechallenging with
TMZ for unselected high-grade gliomas who have relapsed after definitive RT and TMZ.23–25 Approximately
10% of patients in our study received bevacizumab which
has recently been shown to be not active for recurrent
IDH-mutant gliomas in the TAVAREC study. The TAVAREC
study was a randomized phase II study comparing TMZ
alone vs TMZ plus bevacizumab for recurrent grade II-III
astrocytomas without 1p/19q codeletions (65% with confirmed IDH mutation). The addition of bevacizumab to TMZ
failed to improve OS, PFS, or quality of life.26 Altogether,
these data suggest that TMZ or lomustine/PCV should be
considered first-line SST for relapsed IDH-mutant gliomas
whenever possible, and the use of bevacizumab should be
limited. Future clinical trials testing novel agents for recurrent IDH-mutant gliomas may need to consider combining
with AC or testing as second-line salvage therapy after
progression on AC.
The role of reRT for recurrent IDH-mutant gliomas remains undefined. Existing evidence is mostly limited to
small single-institution retrospective studies of low-grade
gliomas without detailed molecular classification, limiting
the comparison to the present investigation.9 Careful selection of patients may achieve efficacy and limit treatment toxicity, as may efforts to reduce total reRT doses,
minimize target volumes, and prolong intervals between
prior RT and reRT.27 The initial results of RTOG 1205, a
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A
IMRT
PBT
Grade 2 or 3
RN with PBT

55

105

8

95
90

6
Frequency

ReRT EQD2 (Gy)

50

100

85

C
IMRT
PBT
Grade 2 or 3
RN with PBT

45
40

2

35

0

100

200 300
PTV (cm3)

400

30

500

D

0

100

200 300
PTV (cm3)

400

0

500

0–5

6–10

11–15

15–20

21–25

26–30

Max Optics Dose From ReRT (Gy)

F

E
8

2

4

3

1

Frequency

Frequency

6

4

2

1
2

0

0
0–10 11–20 21–30 31–40 41–50 51–60 61–70 71–80 81–90

Cumulative Max Dose to Optics (Gy)

0
0–5

6–10

11–15

16–20

21–25 26–30

31–35

Max Brainstem Dose From ReRT (Gy)

36–40

0–10 11–20 21–30 31–40 41–50 51–60 61–70 71–80 81–90

Cumulative Max Dose to Brainstem (Gy)

Figure 3. (A–B) Scatter plot of tumor volume versus reirradiation (reRT) or cumulative EQD2 (biologic equivalent dose at 2 Gy, assuming a/b = 3 for
brain tissue) for a cohort of 18 patients treated with repeat external beam radiation therapy (EBRT) with temozolomide. (C–D) Maximum reRT or cumulative dose to optic structures. (E–F) Maximum reRT or cumulative dose to the brainstem.
  

randomized phase II trial of hypofractionated reRT and
bevacizumab versus bevacizumab alone for recurrent
(mostly IDH-wildtype) GBM, showed that reRT improved
PFS at 6 months but not OS.28 Another small randomized study comparing reRT plus chemotherapy has demonstrated improved PFS for bevacizumab-refractory and
mostly IDH-wildtype GBM (only 8% IDH-mutant) compared
to chemotherapy alone.29 Similarly, we observed early reRT
was associated with improved PFS for the Astro patients
on MVA. Notably, repeat EBRT with TMZ was perhaps the
most common reRT strategy and appeared feasible with an
acceptable rate of sRN. However, selection bias may have
confounded the observed association with improved survival outcomes, such as that the subset of Astro receiving
AC+EBRT had longer disease-free interval since the initial RT and higher proportion with salvage surgery than
those receiving AC alone (Supplementary Table S1). Thus,
prospective clinical trials would be needed to confirm the
benefit of reRT for radiation-relapsed IDH-mutant glioma.
Outside of clinical trial setting and when administered with
AC such as TMZ, we recommend careful patient selection
(such as PTV < 100 cm3) and standard fractionated EBRT to
a dose of 36–45 Gy while limiting the cumulative EQD2 to
below 100 Gy.
The primary limitations of this study include its retrospective design from a single institution and the diverse treatment approaches over a lengthy period. The sample size is
likely limited to detect small effect sizes, especially for the
subset analyses. Given the retrospective nature and lack
of randomized control, selection bias by the treating physicians to choose surgery, AC, or reRT may also confound

the survival benefit observed as evident in Supplementary
Table S1. Thus, the observed associations between treatment
approaches with clinical outcomes should be considered
hypothesis-generating and warrant further validation from
prospective studies. Due to the irregular shape and often diffuse border of these recurrent tumors and the confounding
appearances of treatment-related changes, tumor size and
volume are not included in the multivariable analysis, and
they may have a confounding effect on treatment selection
and prognosis. Furthermore, the toxicities of multiple lines
of alkylating chemotherapy may play an important role in
treatment selection and are not captured in this retrospective analysis, so future prospective studies should also investigate the impact of salvage chemotherapy on patient
reported outcomes and quality of life. Overall, this study supports that radiation-relapsed IDH-mutant gliomas should be
considered for salvage surgery whenever possible and then
receive AC as first-line SST. ReRT may be considered in combination with AC for selected case (focal disease and >2 years
since the initial RT) to improve local control, but its benefit
on survival would need to be clarified in prospective studies.
Future studies to identify additional active systemic agents
for relapsed IDH-mutant gliomas who have progressed on
salvage AC would be an important area of unmet need.

Supplementary Data
Supplementary data are available at Neuro-Oncology
Advances online.
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